Gene therapy: evidence, value and affordability in the US health care system
Abstract
Aims: To explore the challenges presented by gene therapies, discuss potential solutions, and present policy recommendations. Methods: A review of the literature and series of expert interviews were conducted and discussed at a Policy Forum convened by The Institute for Clinical and Economic Review (ICER). The Policy Forum was attended by independent experts and senior representatives from 20 payer organizations and life sciences companies. Results: Three categories of challenges are identified: evidence generation, assessing value and affordability. Possible solutions and policy recommendations are presented for each of the three main categories of challenges. Conclusions: Gene therapies present exciting opportunities, but also pose major challenges. Dialogue between manufacturers and payers around the issues and possible solutions is crucial.
Supplementary Material
File (suppl_table.docx)
- Download
- 28.45 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
American Medical Association. Gene Therapy. http://www.ama-assn.org/ama/pub/physician-resources/medical-science/genetics-molecular-medicine/current-topics/gene-therapy
2.
Genetics Home Reference. How does gene therapy work? https://ghr.nlm.nih.gov/primer/therapy/procedures
3.
MedlinePlus. Genes and Gene Therapy. https://medlineplus.gov/genesandgenetherapy.html
4.
Ylä-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol. Ther. 23(2), 217–218 (2015).
5.
uniQure. uniQure announces it will not seek marketing authorization renewal for Glybera in Europe. http://uniqure.com/GL_PR_Glybera%20withdrawal_FINAL_PDF.pdf
6.
Boliter N. Gene therapies in a bottle – pharma just needs to rub the right way. Pharma intelligence, Informa. September (2016). https://citeline.com/wp-content/uploads/Whitepaper-Report-Gene-Therapy_LR.pdf
7.
Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat. Biotech. 32(1), 40–51 (2014).
8.
Spark Therapeutics. Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene Neparvovec. http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2273905
9.
Marsden G, Towse A, Pearson S, Dreitlein B, Henshall C. Gene therapy: understanding the science, assessing the evidence, and paying for value: a report from the 2016 ICER Membership Policy Summit. Office of Health Economics, London, UK (2017).
•• Full description of the Institute for Clinical and Economic Review Policy Summit on Gene Therapy with greater detail on the challenges around evidence generation, value assessment and affordability, and recommendations for both payers and pharmaceutical manufacturers.
10.
Bubela T, McCabe C, Archibald P et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen. Med. 10(7), 897–911 (2015).
11.
Hettle R, Corbett M, Hinde S et al. Exploring the assessment and appraisal of regenerative medicines and cell therapy products. CRD/CHE University of York, York, UK (2016).
•• Provides a review of previous evaluations of regenerative medicines in the UK, discussions around the use of different types of evidence of informing decision making, and a mock health technology assessment appraisal of chimeric antigen receptor T-cell therapy.
12.
van Schothorst M, Weeda J, Schiffers K et al. Study on the regulation of advanced therapies in selected jurisdictions. European Commission (2014).
13.
Abou-El-Enein M, Bsanhoury A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell 19, 292–297 (2016).
14.
Abou-El-Enein M, Bauer G, Medcalf N, Volk H, Reinke P. Putting a price tag on novel autologous cellular therapies. Cytotherapy 18, 1056–1061 (2016).
15.
Towse A, Barnsley P. Approaches to identifying, measuring and aggregating elements of value. Int. J. Technol. Assess. Health Care 29(4), 360–364 (2013).
16.
The Institute for Clinical and Economic Review. ICER Value Assessment Framework 1.0 to 2.0. http://icer-review.org/wp-content/uploads/2016/02/Value-Assessment-Framework-slides-for-July-29-webinar-FINAL-corrected-8--22--1.pdf
17.
Oortwijn W, Sampietro-Colom L, Habens F. Developments in value frameworks to inform the allocation of healthcare resources. Int. J. Technol. Assess. Health Care 33(2), 323–329 (2017).
18.
Genetic and Rare Diseases Information Center (GARD). FAQs about rare diseases. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases
19.
Spark Therapeutics. 2016 annual report. http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY3MTY4fENoaWxkSUQ9Mzc1MDA1fFR5cGU9MQ==&t=1
20.
Neumann P, Cohen J. Measuring the value of prescription drugs. N. Engl. J. Med. 373, 2595–2597 (2015).
21.
Westrich K. Current landscape: value assessment frameworks. National Pharmaceutical Council, Washington, DC, USA (2016).
22.
Garrison LP, Carlson J, Bajaj P et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am. J. Manag. Care 21(9), 632–640 (2015).
23.
Garrison LP, Towse A, Briggs A et al. Performance-based risk-sharing – good practices for design, implementation, and evaluation: report of the ISPOR Good Practices for Performance-based Risk-Sharing Task Force. Value Health 16(5), 703–719 (2015).
• Describes different types of performance-based risk sharing arrangements and outlines principles of good practice.
24.
APM Health Europe. Prices of new hepatitis C combinations lower than monotherapy in Spain in six months. www.apmhealtheurope.com/Prices-of-new-hepatitis-C-combinations-lower-than-monotherapy-in-Spain-in-six-months-FS_41696.html
25.
Gottlieb S, Carino T. Establishing new payment provisions for the high cost of curing disease. AEI Research (2014). www.aei.org/wp-content/uploads/2014/07/-establishing-new-payment-provisions-for-the-high-cost-of-curing-disease_154058134931.pdf
• Explores credit and contracting arrangements for amortizing the cost of therapies over a number of years to provide new funding options for high-cost therapies.
26.
Montazerhodjat V, Weinstock D, Lo A. Buying cures versus renting health: financing health care with consumer loan. Sci. Transl. Med. 8(327), 327ps6 (2016).
• Discusses health care loans as a means to improve affordability for large health care expenses, whilst maintaining incentives for manufactures to develop innovative therapies.
27.
US FDA. www.fda.gov
28.
Bailey AM, Arcidiacono J, Benton KA, Taraporewala Z, Winitsky S. United States Food and Drug Administration regulation of gene and cell therapies. Adv. Exp. Med. Biol. 871, 1–29 (2015).
Information & Authors
Information
Published In
Copyright
© 2017 Institute for Clinical and Economic Review.
History
Received: 30 August 2017
Accepted: 11 October 2017
Published online: 16 November 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Gene therapy: evidence, value and affordability in the US health care system. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0068
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Sumaya Abuloha, Amie Goodin, Tianze Jiao, Manuela Corti, Mikael Svensson, Modeling the Budget Impact of Disease-Modifying Therapies in Infantile-Onset Spinal Muscular Atrophy, Clinical Drug Investigation, 10.1007/s40261-026-01571-x, (2026).
- Walter Van Dyck, Sissel Michelsen, David Veredas, Isabelle Huys, Jeroen Luyten, Steven Simoens, When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact Simulation, Journal of Market Access & Health Policy, 10.3390/jmahp14020023, 14, 2, (23), (2026).
- Yi Han, Mattia Andreoletti, Timo Minssen, Effy Vayena, Kelly E. Ormond, The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe, Journal of Community Genetics, 10.1007/s12687-026-00860-4, 17, 1, (2026).
- Sk Ashif Jan, Abhijit Debnath, Rajesh Kumar Singh, Pankaj Kumar Tyagi, Sachin Singh, Anil Kumar Singh, Targeting Undruggable Proteins: The siRNA Revolution Beyond Small Molecules - Advances, Challenges, and Future Prospects in Therapeutic Innovation, Current Gene Therapy, 10.2174/0115665232357160250123113148, 26, 1, (116-135), (2026).
- Nermina Ferizović, Caroline S. Clarke, Rachael M. Hunter, Ruth Plackett, Nicholas Freemantle, Value attributes of advanced therapy medicinal products: a comprehensive literature review, Discover Medicine, 10.1007/s44337-025-00376-9, 2, 1, (2025).
- Harshini Hariram, Sean P. Gavan, Constraints on delivering cell and gene therapies identified during technology appraisal by the National Institute for Health and Care Excellence, International Journal of Technology Assessment in Health Care, 10.1017/S0266462325100391, 41, 1, (2025).
- L. Evert, T. Potupchik, O. Veselova, I. Svetlakova, B. Panchenko, R. Kudasheva, A. Melnikova, Genome editing in neurodegenerative diseases: risk analysis, technological challenges, and prospects for clinical application, Molekulyarnaya Meditsina (Molecular medicine), 10.29296/24999490-2025-02-03, (21-31), (2025).
- Simona Cosma, Stefano Cosma, Daniela Pennetta, Giuseppe Rimo, Overcoming the “valleys of death” in advanced therapies: The role of finance, Social Science & Medicine, 10.1016/j.socscimed.2024.117639, 366, (117639), (2025).
- Nadezhda A. Pechnikova, Malamati Poimenidou, Ioannis Iliadis, Maria Zafeiriou-Chatziefraimidou, Aleksandra V. Iaremenko, Tamara V. Yaremenko, Kalliopi Domvri, Alexey V. Yaremenko, Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the Horizon, Journal of Clinical Medicine, 10.3390/jcm14030898, 14, 3, (898), (2025).
- RENA M. CONTI, PATRICK DEMARTINO, JONATHAN GRUBER, ANDREW W. LO, YUTONG SUN, JACKIE WU, Innovative Insurance to Improve US Patient Access to Cell and Gene Therapy, The Milbank Quarterly, 10.1111/1468-0009.12728, 103, 1, (32-51), (2025).
- See more